Biosensors Int'l, Terumo, will market Nobori stent in Japan

Terumo's Nobori drug-eluting stent--courtesy of Terumo

Biosensors International will work with Japan's Terumo to promote that company's Nobori drug-eluting stent in Japan. They'll focus on specific specialist cardiology centers in a deal that begins in April and is designed to last at least three years. It also makes practical sense. That's because Nobori already uses Biosensors' technology in two ways--the Bioliumus A9 drug and an abluminal biodegradable polymer coating. The companies are fast friends, essentially; before their co-promotion deal they renewed their technology licensing agreement at least through 2014. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.